secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016272
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals subsidiary HOPE signs definitive agreement to acquire Kadima Neuropsychiatry Institute
--------------------------------------------------------------------------------

- Kadima is a profitable interventional psychiatry clinic in La Jolla, CA, expected to serve as clinical model for HOPE network.
- Dr. David Feifel, Kadima founder, to join HOPE as Chief Medical Innovation Officer upon closing.
- Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE.
- Closing subject to customary conditions and finalization of financing; further details to follow.
- Kadima is a leading investigative site for CNS and psychedelic research, including ketamine and TMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925016272/0001437749-25-016272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925016272/nrxp20250513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer